Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iodixanol
Drug ID BADD_D01178
Description Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents.
Indications and Usage Iodixanol is a contrast agent during coronary angiography.
Marketing Status approved
ATC Code V08AB09
DrugBank ID DB01249
KEGG ID D01474
MeSH ID C044834
PubChem ID 3724
TTD Drug ID D0Y4YG
NDC Product Code 71806-222; 65219-381; 0407-2223; 65219-383; 0407-2222; 57884-0029
UNII HW8W27HTXX
Synonyms iodixanol | Visipaque | Visipaque Unique Softpac | iodixanol-320 | contrast media 2-5410-3
Chemical Information
Molecular Formula C35H44I6N6O15
CAS Registry Number 92339-11-2
SMILES CC(=O)N(CC(CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)C)O)C2=C(C(= C(C(=C2I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ventricular arrhythmia02.03.04.006--
Ventricular fibrillation02.03.04.0080.017783%
Ventricular tachycardia02.03.04.0100.014227%
Vertigo17.02.12.002; 04.04.01.0030.028454%
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Visual impairment06.02.10.0130.024897%Not Available
Vomiting07.01.07.0030.246123%
Wheezing22.03.01.0090.022763%
Coronary artery dissection24.02.02.001; 02.02.01.004; 12.02.01.0350.015649%Not Available
Acute generalised exanthematous pustulosis11.07.01.018; 10.01.01.034; 23.03.10.002; 12.03.01.0050.039124%Not Available
Hypoacusis04.02.01.006--
Emotional distress19.04.02.008--Not Available
Muscle tightness15.05.03.0070.007113%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.007113%Not Available
Skin tightness23.03.03.0180.007113%Not Available
Systemic inflammatory response syndrome24.06.03.008; 10.02.01.008; 08.01.05.0050.007113%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Eye pruritus06.04.05.0060.052639%Not Available
Nasal discomfort22.12.03.0120.007113%Not Available
Musculoskeletal stiffness15.03.05.0270.026320%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Skin swelling23.03.03.0390.007113%Not Available
Type IV hypersensitivity reaction10.01.03.0220.031299%Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.022763%Not Available
Haemorrhage24.07.01.002--Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.010670%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.041969%Not Available
Toxic skin eruption23.03.05.003; 10.01.01.008; 12.03.01.0730.017783%Not Available
Angiopathy24.03.02.007--Not Available
Hot flush08.01.03.027; 24.03.01.005; 21.02.02.0010.010670%
The 9th Page    First    Pre   9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene